What Tiobarbital Braun Treats: Main Uses and Benefits

Tiobarbital Braun is commonly used in clinical settings that involve acute or unstable symptom patterns. Its use is applied across three main therapeutic domains where additional symptomatic support is needed. Its applications include induction for general anesthesia, control of severe convulsive episodes (refractory status epilepticus), and the management of critically elevated intracranial pressure (ICP).

---

Induction for General Anesthesia

This medication is commonly used to help with the immediate and profound loss of consciousness required at the start of a surgical procedure. It supports the patient by helping to achieve a rapid and controlled transition into a hypnotic state, which contributes to improved comfort during periods of heightened physiological activity associated with pre-operative preparation.

Management in Acute Neurological Crises

Tiobarbital Braun is applied in addressing conditions characterized by heightened symptoms, such as refractory status epilepticus or critically elevated pressure within the skull. It helps manage intense and disruptive symptoms of increased neurological activity, which provides support for maintaining functional stability by reducing high pressure levels and controlling convulsive episodes.

---

Quick Fact: Relief for Acute Neurological Stress Tiobarbital Braun is used in acute clinical scenarios, such as the Intensive Care Unit (ICU) and emergency settings, when symptoms of neurological stress (like uncontrolled seizures or high ICP) become temporarily overwhelming and require immediate support.

Regulatory References

1. Health Products Regulatory Authority (HPRA) SmPC overview

Eligibility Map: Who can and cannot use Tiobarbital Braun — official regulatory information

This eligibility profile is based strictly on contraindication and special populations sections of authoritative government regulatory documents.

Eligibility Scope	Details
Populations for whom use is contraindicated	Patients with known hypersensitivity to barbiturates, a history of acute porphyria (intermittent or variegate), severe shock, dystrophia myotonica, or acute respiratory obstruction (e.g., status asthmaticus).
Populations for whom use is restricted	Elderly or debilitated patients, those with severe cardiovascular disease, adrenocortical insufficiency (Addison's disease), myasthenia gravis, or conditions causing hypovolemia (e.g., severe hemorrhage, burns).

Age-related Eligibility Rules

• Pediatric Use: Use is generally established for anesthesia induction in infants and children, but the dosage must be highly individualized based on age, weight, and general condition.
• Older Adults (Geriatric): Use requires special caution and a reduced initial dose due to slower drug metabolism and increased risk of prolonged effects.

Condition-Specific Eligibility

• Hepatic and Renal Impairment: Doses must be reduced in patients with liver impairment, as the drug is primarily metabolized by the liver. Use also requires caution in severe kidney disease.

Pregnancy and Lactation Eligibility Status

• Pregnancy: The drug readily crosses the placental barrier and should be given only if the expected benefits clearly outweigh potential risks to the fetus (often cited as Pregnancy Category C).
• Lactation: Thiopental appears in breast milk. Regulatory guidance advises that breastfeeding should be temporarily suspended (e.g., for at least 12 hours) following administration.

---

The regulatory documents clearly define who can and cannot use the medicine by establishing a strict set of absolute prohibitions, primarily related to allergic history and certain metabolic/acute respiratory conditions. For all other populations, eligibility is conditional, requiring increased caution and mandatory dose adjustments for physiological factors such as advanced age or organ system impairment.

Interactions with other medicines and products

Tiobarbital Braun’s interaction profile is structured around official documentation regarding synergistic effects, required dose adjustments, and formal restrictions with other substances and certain patient conditions.

Formal Restrictions and Incompatibilities

Administration is formally contraindicated in patients with Porphyria, as this applies to the entire barbiturate class according to regulatory guidelines. The prepared solution is strongly alkaline and must not be mixed with acidic anesthetic solutions or volume replacement solutions due to the documented risk of physical precipitation. Furthermore, alcohol consumption should be avoided after administration due to the documented risk of enhanced psychomotor impairment with residual effects.

Pharmacodynamic Interactions

Co-administration with CNS depressant drugs, including opioid analgesics and benzodiazepines, is officially noted to potentiate the respiratory depressant effect and produce synergistic CNS depression. Similarly, many antihypertensive agents (such as ACE inhibitors and beta-blockers) interact to cause an enhanced hypotensive effect. Antidepressants, including Tricyclics and MAOIs, also carry a documented risk of arrhythmias and altered blood pressure when combined with this medicine.

Exposure and Effect Modification

Agents that officially alter the drug's effect include Sulphonamides, which formally enhance the effects of Thiopental sodium. Substances used for pre-treatment, such as Aspirin and Probenecid, are also documented to potentiate the anesthetic effect. In cases of hepatic impairment or severe renal disease, the hypnotic effect may be prolonged or potentiated due to altered clearance.

How Tiobarbital Braun Works

Tiobarbital Braun's action is exerted through the central nervous system's ( CNS) GABA-mediated inhibitory signaling pathway. It functions as a CNS depressant by modulating activity at the molecular level, which results in a global reduction in brain excitability.

Enhanced Inhibitory Neurotransmission via the GABA-A Receptor

The drug's primary action is on the GABA-A receptor complex. Tiobarbital Braun acts as a positive allosteric modulator, binding to the receptor to amplify the effects of the inhibitory neurotransmitter GABA. This key interaction prolongs the opening of the receptor's associated chloride ion channel, which enhances negative charge flow across the neuronal membrane.

Neuronal Hyperpolarization and CNS Signal Dampening

The prolonged opening of the chloride channel allows an influx of negatively charged chloride ions ( Cl^-) into the neuron. This shifts the internal electrical charge, causing hyperpolarization and making the neuron less susceptible to firing an action potential. This rapid membrane stabilization process leads to a reduction in high-frequency neural signal transmission.

Coupling to Reduced Cerebral Metabolic Rate

The widespread suppression of electrical activity is physiologically coupled to a significant reduction in the brain's demand for oxygen and energy. This effect on the brain's cerebral metabolic rate of oxygen ( CMRO2) and cerebral blood flow ( CBF) is a direct consequence of the reduced neural work, contributing to the drug's overall depressant effect profile.

How to use Tiobarbital Braun: Official Administration Guidelines

Tiobarbital Braun (Thiopental Sodium) is administered exclusively via the intravenous (IV) route. Due to the significant variation in patient response, there are no fixed dosage recommendations; the dose must be carefully titrated against the patient's requirements and clinical response, taking into account factors like age, sex, and body weight.

Preparation and Dosing

The drug is supplied as a sterile powder for solution for injection, typically reconstituted with Sterile Water for Injection to a concentration of 2.0% to 2.5% w/v (e.g., 500 mg in 20 mL). Concentrations lower than 2.0% are not used with this diluent due to the risk of hemolysis. The prepared solution should be used promptly and must be discarded within a few hours (typically seven hours).

To begin, a test dose of 25 mg to 75 mg is advisable to gauge patient sensitivity, followed by a waiting period of at least 60 seconds to observe the reaction. Induction of anesthesia in the average adult is commonly achieved by injecting 50 mg to 75 mg at intervals of 20 to 40 seconds. The injection should always be slow to minimize the risk of overdosage and respiratory depression.

Administration Schedule

• Adult Anesthesia Induction: Dosage is typically 3 to 4 mg/kg (for a 70 kg adult, 210 mg to 280 mg) administered in fractional doses for rapid induction in balanced anesthesia.
• Maintenance: Anesthesia can be maintained with small, repeated intermittent doses (25 mg to 50 mg) as needed, or by a continuous intravenous drip using a 0.2% or 0.4% concentration, with the infusion rate adjusted to control the depth of anesthesia.
• Pediatric Use: Initial doses vary by age, generally ranging from 3 to 8 mg/kg intravenously for induction, and about 1 mg/kg for maintenance, but must always be individually determined by the physician.

Note: This drug must only be administered by qualified personnel in a setting where equipment for assisted or controlled ventilation is immediately available.

Research evidence / Overview of studies for Tiobarbital Braun

Evidence for Use in General Anesthesia Induction

Tiobarbital Braun was studied to explore its use in rapidly achieving a hypnotic state necessary for general anesthesia. The research in this area primarily consists of Randomized Controlled Trials and comparison studies. These studies monitored outcomes describing episodic or acute changes—specifically, how quickly unconsciousness occurs—and outcomes monitoring physiological strain or stress during the initial process. The data describe patterns related to the time taken to achieve a hypnotic state, with research also examining airway metrics were monitored after administration. This research provides insight into short-term changes relevant for surgery. However, the results apply only to the specific populations studied, and comparative evidence is lacking against some of the newer agents that have since become available for this purpose.

---

Research on Acute Neurological Crises

Research has evaluated Tiobarbital Braun in conditions associated with acute or disruptive episodes, specifically very severe, uncontrolled seizures (refractory status epilepticus) and critically elevated pressure inside the skull (intracranial pressure or ICP). Given the urgent nature of these conditions involving periods of heightened symptoms, the evidence often comes from smaller observational studies, retrospective reviews, and case series rather than large clinical trials. These studies monitored outcomes related to systemic or functional imbalance. For severe seizures that can not be controlled by other medications, research examined the association with the duration of this state of heightened symptom activity. When used to address high ICP, research examined how monitored pressure readings changed when the drug was observed in patients, but because of the complexity of these cases, findings were mixed regarding long-term functional recovery.

---

Long-Term Studies and Follow-up Durations

Since Tiobarbital Braun is used solely for acute, immediate medical needs, follow-up durations were limited in the vast majority of studies. The initial research focused on the immediate stabilization of outcomes capturing phases of heightened symptom activity, which takes place over minutes, hours, or a few days. The research highlights changes measured only during that initial study period. Therefore, long-term effects are not fully established. There is limited information for long-term outcomes regarding the durability of the initial response, or any potential effects years after a single, acute treatment.

---

What Is Still Uncertain About Tiobarbital Braun's Research Base

The current evidence highlights both what is known and what is still uncertain. Overall, the evidence quality varies across studies, depending on the medical situation. While the evidence for its acute use in general anesthesia induction is substantial, the research in acute neurological crises is often based on smaller, observational data where certainty remains low. Comparative evidence is lacking when Tiobarbital Braun is compared head-to-head with some newer agents now available for acute interventions. Addressing these evidence gaps and limitations is an area where research is ongoing, as documented in the scientific literature.

Common questions about Tiobarbital Braun (FAQ)

---

Q: What is the general duration of effect after Tiobarbital Braun is given?

Tiobarbital Braun is classified as an ultrashort-acting medicine. The effect of inducing a hypnotic state begins rapidly, usually within 30 to 40 seconds of being administered into the vein. After a single, small dose, recovery is typically quick. However, official information notes that if repeated doses are given, the overall duration of the effects can be prolonged.

---

Q: Do people feel groggy or confused after Tiobarbital Braun is stopped?

Following administration, recovery can be accompanied by effects like somnolence, which is a state of drowsiness. Regulatory documents also note that retrograde amnesia may occur, which is a temporary loss of memory for the events immediately surrounding the time the drug was administered. These effects may be observed during the recovery process from anesthesia.

---

Q: Can Tiobarbital Braun affect the way my pain medication works?

Official prescribing information indicates that co-administration with opioid analgesics, a common type of pain medication, can interact with Tiobarbital Braun. This combination is noted to potentiate, or increase, the depressant effect on breathing. Official guidance emphasizes the importance of informing the physician about all medications being taken.

---

Q: Is Tiobarbital Braun safe for people with kidney problems?

Official regulatory documents require special caution when Tiobarbital Braun is used in patients with severe renal (kidney) dysfunction. Because the body relies on the kidneys to help eliminate the drug’s byproducts, kidney impairment can lead to a prolonged or increased hypnotic effect. In such cases, dose adjustments may be necessary as directed by the prescribing physician.

---

Q: What kind of research has been done on Tiobarbital Braun in children?

Regulatory documents acknowledge that the use of Tiobarbital Braun for anesthesia induction in infants and children is established. Official information emphasizes that the dosage is individually determined by the physician based on the child's age, weight, and general clinical status.

---

Q: What happens if Tiobarbital Braun gets outside the vein during injection?

Accidental injection of the solution outside the vein, known as extravasation, is a serious risk documented in the official safety information. This can cause pain and swelling at the injection site. It can also lead to serious local tissue injury, which may result in tissue necrosis (tissue death).

---

Q: Why is this medication given through a drip or injection and not a pill?

Tiobarbital Braun is formulated as a powder that must be dissolved into a sterile solution for intravenous (IV) administration. The IV route is necessary because the medication requires rapid access to the central nervous system (CNS). This immediate action is necessary to quickly achieve the deep central nervous system depression required for anesthesia induction.

---

Q: Does Tiobarbital Braun have a risk of dependence or withdrawal?

Tiobarbital Braun belongs to the barbiturate class of drugs, which regulatory bodies note are capable of producing both physical and psychological dependence. The drug is classified as habit forming. If used for a prolonged period, abrupt discontinuation could result in withdrawal symptoms.

---

Q: What are the specific signs of a serious reaction to Tiobarbital Braun?

Official adverse effects information lists serious reactions that require immediate attention, such as anaphylactic shock (a severe allergic reaction) and acute circulatory failure. Documented effects that may indicate a reaction include sudden hypotension (low blood pressure), severe respiratory depression, and laryngospasm (a spasm of the vocal cords that affects breathing).

---

Q: Are there studies on how Tiobarbital Braun is processed by the body?

Official clinical pharmacology information describes how the drug is processed. Due to its high lipid solubility, the active ingredient crosses the blood-brain barrier very quickly. It is primarily degraded, or broken down, in the liver, and the resulting inactive byproducts are mostly eliminated from the body through the urine.

---

Q: What precautions are taken before a patient is given Tiobarbital Braun?

Official documents outline several necessary precautions, including performing a small test dose to check the patient's sensitivity. Furthermore, the product information states that the administration setting has equipment and staff readily available for assisted or controlled ventilation, due to the risk of respiratory depression.

---

Q: What happens to Tiobarbital Braun after its effects wear off?

The drug is chemically broken down in the body. According to clinical pharmacology information, the liver is the primary organ responsible for degrading the active drug into inactive byproducts. These byproducts are then cleared from the body, mostly through the kidneys and excreted in the urine.

---

Q: What should a patient tell their doctor about before receiving Tiobarbital Braun?

Official safety information highlights several conditions and allergies that are important to disclose, such as a known allergy to barbiturates or a history of Porphyria. The official warnings also emphasize the necessity of informing the physician about all other medications, including central nervous system depressants or blood pressure medications, as well as pregnancy and lactation status.

---

Q: What is the maximum amount of Tiobarbital Braun typically used in a procedure?

Official administration guidelines state that there are no fixed dosage recommendations for this drug. The exact amount administered is carefully adjusted, or titrated, by qualified medical personnel based on the patient’s immediate clinical needs and response during the procedure.

---

Q: How common are hypersensitivity reactions to Tiobarbital Braun?

While hypersensitivity reactions are known to occur, official regulatory documents classify life-threatening reactions, such as anaphylactic shock, as less common adverse effects. These serious events are carefully monitored for in the administration setting. Hypersensitivity to any component of the drug is listed as a contraindication for its use.

---

Q: Is Tiobarbital Braun classified as a controlled substance?

Yes, the active ingredient, thiopental sodium, is officially classified as a Schedule III controlled substance under regulatory acts in the United States. This classification indicates that the drug has accepted medical use but also carries a potential for abuse or dependence.

---

Q: Are there different brand names for the same medication as Tiobarbital Braun?

The active ingredient in Tiobarbital Braun is thiopental sodium. This substance has been sold under various trade names globally, including Pentothal, and may be referred to by its generic name. Tiobarbital Braun is a specific preparation manufactured by B. Braun.

---

Q: What are the concerns for patients taking Tiobarbital Braun who are also on blood thinners?

Official information notes that barbiturates, the class of drugs Tiobarbital Braun belongs to, can affect how the liver processes certain medications. This may accelerate the metabolism of oral anticoagulants, or blood thinners, which could potentially reduce their effect. The prescribing physician determines if dosage adjustments for the blood thinner are necessary.

---

Q: Is Tiobarbital Braun associated with temporary memory loss?

Yes, official clinical pharmacology documents mention that recovery after a dose may be accompanied by retrograde amnesia. This is a temporary form of memory loss specifically related to events that happened just before and during the administration of the drug. Somnolence (drowsiness) is also noted.

---

Q: What measures are in place to monitor a patient receiving Tiobarbital Braun?

Due to the risk of cardiovascular and respiratory depression, continuous monitoring of the patient's vital functions is performed during and immediately following administration. Official warnings state that the drug is given only in a setting where equipment for assisted or controlled ventilation and oxygen is immediately available to manage potential complications.

---

Q: Does Tiobarbital Braun affect the function of the thyroid gland?

Regulatory information documents that barbiturates, as a class, are known to accelerate the body's metabolism of thyroid hormones. This could potentially lead to decreased levels of thyroid hormones in the blood. Official guidance indicates that all pre-existing conditions and current medications should be disclosed to the prescribing physician.

How to Store and Dispose of Tiobarbital Braun?

The storage and disposal of Tiobarbital B. Braun are governed by official regulatory standards to maintain stability and ensure environmental safety.

Storage Requirements

Condition	Requirement (Official Labeling)
Temperature	Store the unconstituted powder below 25°C (Controlled Room Temperature).
Protection	Keep the product in the original container and protect from light.
Child Safety	Store the medicine out of the sight and reach of children.

Post-Reconstitution Stability

The prepared solution must be used immediately after reconstitution. Any unused portion of the solution must be discarded promptly, as the liquid form has limited stability.

Disposal Instructions

Official guidelines mandate that unused or expired Tiobarbital B. Braun must not be disposed of via wastewater or household waste. Disposal must be carried out according to local regulatory requirements using established pharmaceutical waste collection systems.